Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
11
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with Truvada
Cmax, Cmin with 90% confidence (emtricitabine 200 mg, tenofovir
intervals if available disoproxil 245 mg)
(mechanism)
ANTI-INFECTIVES
Hepatitis B virus (HBV) antiviral agents
Adefovir dipivoxil/Tenofovir Adefovir dipivoxil: Adefovir dipivoxil and Truvada
disoproxil AUC: ↓ 11% (↓ 14 to ↓ 7) should not be administered
Cmax: ↓ 7% (↓ 13 to ↓ 0) concomitantly (see section 4.4).
Cmin: NC
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Tenofovir:
AUC: ↓ 1% (↓ 8 to
↑ 6)
Cmax: ↑ 7% (↓ 6 to
↑ 22)
Cmin: NC
ANTI-INFECTIVES
Hepatitis B virus (HBV) antiviral agents
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
11
Lamivudine/Tenofovir disoproxil Lamivudine: Lamivudine and
AUC: ↓ 3% (↓ 8% to ↑ 15) Emtricitabine/Tenofovir disoproxil
Cmax: ↓ 24% (↓ 44 to ↓ 12) Krka should not be administered
Cmin: NC concomitantly (see section 4.4).
Tenofovir:
AUC: ↓ 4% (↓ 15 to ↑ 8)
Cmax: ↑ 102% (↓ 96 to ↑ 108)
Cmin: NC
Efavirenz/Tenofovir disoproxil Efavirenz: No dose adjustment of efavirenz is
AUC: ↓ 4% (↓ 7 to ↓ 1) required.
Cmax: ↓ 4% (↓ 9 to ↑ 2)
Cmin: NC
Tenofovir:
AUC: ↓ 1% (↓ 8 to ↑ 6)
Cmax: ↑ 7% (↓ 6 to ↑ 22)
Cmin: NC
ANTI-INFECTIVES
Hepatitis B virus (HBV) antiviral agents
Adefovir dipivoxil /Tenofovir Adefovir dipivoxil: Adefovir dipivoxil and
disoproxil AUC: ↓ 11% (↓ 14 to ↓ 7) Emtricitabine/Tenofovir disoproxil
Cmax: ↓ 7% (↓ 13 to ↓ 0) Krka should not be administered
Cmin: NC concomitantly (see section 4.4).
Tenofovir:
AUC: ↓ 2% (↓ 5 to ↑ 0)
Cmax: ↓ 1% (↓ 7 to ↑ 6)
Cmin: NC
Hepatitis C virus (HCV) antiviral agents
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of
(90 mg/400 mg q.d.) + AUC: ↑ 96% (↑ 74 to ↑ 121) tenofovir resulting from co-
Atazanavir/Ritonavir Cmax: ↑ 68% (↑ 54 to ↑ 84) administration of tenofovir disoproxil,
(300 mg q.d./100 mg q.d.) + Cmin: ↑ 118% (↑ 91 to ↑ 150) ledipasvir/sofosbuvir and
Emtricitabine/Tenofovir disoproxil Sofosbuvir: atazanavir/ritonavir may increase
(200 mg/245 mg q.d.)1 AUC: ↔ adverse reactions related to tenofovir
Cmax: ↔ disoproxil, including renal disorders.
GS-3310072: The safety of tenofovir disoproxil when
AUC: ↔ used with ledipasvir/sofosbuvir and a
Cmax: ↔ pharmacokinetic enhancer (e.g.
Cmin: ↑ 42% (↑ 34 to ↑ 49) ritonavir or cobicistat) has not been
Atazanavir: established.
AUC: ↔ The combination should be used with
Cmax: ↔ caution with frequent renal monitoring,
Cmin: ↑ 63% (↑ 45 to ↑ 84) if other alternatives are not available
Ritonavir: (see section 4.4).
AUC: ↔
Cmax: ↔
Cmin: ↑ 45% (↑ 27 to ↑ 64)
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↔
Cmax: ↑ 47% (↑ 37 to ↑ 58)
Cmin: ↑ 47% (↑ 38 to ↑ 57)
Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations of
(90 mg/400 mg q.d.) + AUC: ↔ tenofovir resulting from co-
Darunavir/Ritonavir Cmax: ↔ administration of tenofovir disoproxil,
(800 mg q.d./100 mg q.d.) + Cmin: ↔ ledipasvir/sofosbuvir and
Emtricitabine/Tenofovir disoproxil Sofosbuvir: darunavir/ritonavir may increase
(200 mg/245 mg q.d.)1 AUC: ↓ 27% (↓ 35 to ↓ 18) adverse reactions related to tenofovir
12
Cmax: ↓ 37% (↓ 48 to ↓ 25) disoproxil, including renal disorders.
GS-3310072: The safety of tenofovir disoproxil when
AUC: ↔ used with ledipasvir/sofosbuvir and a
Cmax: ↔ pharmacokinetic enhancer (e.g.
Cmin: ↔ ritonavir or cobicistat) has not been
Darunavir: established.
AUC: ↔ The combination should be used with
Cmax: ↔ caution with frequent renal monitoring,
Cmin: ↔ if other alternatives are not available
Ritonavir: (see section 4.4).
AUC: ↔
Cmax: ↔
Cmin: ↑ 48% (↑ 34 to ↑ 63)
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↑ 50% (↑ 42 to ↑ 59)
Cmax: ↑ 64% (↑ 54 to ↑ 74)
Cmin: ↑ 59% (↑ 49 to ↑ 70)
Ledipasvir/Sofosbuvir Ledipasvir: No dose adjustment is recommended.
(90 mg/400 mg q.d.) + AUC: ↓ 34% (↓ 41 to ↓ 25) The increased exposure of tenofovir
Efavirenz/Emtricitabine/Tenofovir Cmax: ↓ 34% (↓ 41 to ↑ 25) could potentiate adverse reactions
disoproxil Cmin: ↓ 34% (↓ 43 to ↑ 24) associated with tenofovir disoproxil,
(600 mg/200 mg/245 mg q.d.) Sofosbuvir: including renal disorders. Renal
AUC: ↔ function should be closely monitored
Cmax: ↔ (see section 4.4).
GS-3310072:
AUC: ↔
Cmax: ↔
Cmin: ↔
Efavirenz:
AUC: ↔
Cmax: ↔
Cmin: ↔
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Tenofovir:
AUC: ↑ 98% (↑ 77 to ↑ 123)
Cmax: ↑ 79% (↑ 56 to ↑ 104)
Cmin: ↑ 163% (↑ 137 to ↑ 197)
Ledipasvir/Sofosbuvir Ledipasvir: No dose adjustment is recommended.
(90 mg/400 mg q.d.) + AUC: ↔ The increased exposure of tenofovir
Emtricitabine/Rilpivirine/ Tenofovir Cmax: ↔ could potentiate adverse reactions
disoproxil Cmin: ↔ associated with tenofovir disoproxil,
(200 mg/25 mg/245 mg q.d.) Sofosbuvir: including renal disorders. Renal
AUC: ↔ function should be closely monitored
Cmax: ↔ (see section 4.4).
GS-3310072:
AUC: ↔
Cmax: ↔
Cmin: ↔
Emtricitabine:
AUC: ↔
Cmax: ↔
Cmin: ↔
Rilpivirine:
AUC: ↔
Cmax: ↔
13
Cmin: ↔
Tenofovir:
AUC: ↑ 40% (↑ 31 to ↑ 50)
Cmax: ↔
Cmin: ↑ 91% (↑ 74 to ↑ 110)
Ledipasvir/Sofosbuvir Sofosbuvir: No dose adjustment is required. The
(90 mg/400 mg q.d.) + Dolutegravir AUC: ↔ increased exposure of tenofovir could
(50 mg q.d.) + Cmax: ↔ potentiate adverse reactions associated
Emtricitabine/Tenofovir disoproxil with tenofovir disoproxil, including
(200 mg/245 mg q.d.) GS-3310072 renal disorders. Renal function should
AUC: ↔ be closely monitored (see section 4.4).
Cmax: ↔
Cmin: ↔
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-01-31T12:47:00Z · SHA-256 bff22a935481266901d4c92f1163f09cb1d50edd80ede33ac1750318fed62b8d · Passage ef1a7c3e42b38e99972a859eaae7af1573783b27f7b434b743e8cd7a9897fd81 · Zeichen 7896–17795 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.